Ifosfamide plus oral etoposide salvage chemotherapy for platinum-resistant paclitaxel-pretreated ovarian cancer

Απλή σελίδα τεκμηρίου
dc.contributor.authorAravantinos, G.en
dc.contributor.authorDimopoulos, M. A.en
dc.contributor.authorKosmidis, P.en
dc.contributor.authorBafaloukos, D.en
dc.contributor.authorPapadimitriou, C.en
dc.contributor.authorKiamouris, C.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorSikiotis, K.en
dc.contributor.authorPapakostas, P.en
dc.contributor.authorSkarlos, D. V.en
dc.date.accessioned2015-11-24T19:12:13Z
dc.date.available2015-11-24T19:12:13Z
dc.identifier.issn0923-7534-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/21038
dc.rightsDefault Licence-
dc.subjectAdministration, Oralen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Agents, Phytogenic/administration & dosageen
dc.subjectAntineoplastic Combined Chemotherapy Protocols/administration &en
dc.subjectdosage/*therapeutic useen
dc.subjectDisease Progressionen
dc.subjectDrug Resistance, Neoplasmen
dc.subjectEtoposide/administration & dosageen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectIfosfamide/administration & dosageen
dc.subjectInfusions, Intravenousen
dc.subjectMiddle Ageden
dc.subjectOvarian Neoplasms/*drug therapy/pathologyen
dc.subjectPaclitaxel/pharmacologyen
dc.subjectPrognosisen
dc.subjectSalvage Therapyen
dc.subjectSurvival Analysisen
dc.titleIfosfamide plus oral etoposide salvage chemotherapy for platinum-resistant paclitaxel-pretreated ovarian canceren
heal.abstractBACKGROUND: The prognosis of platinum resistant ovarian cancer is very poor and the treatment of choice has not been clearly defined. PATIENTS AND METHODS: We conducted a phase II study with the combination of ifosfamide i.v. at 2.25 g/m2 (days 1, 2) and etoposide per os at 100 mg daily (days 1-10) every four weeks. To be eligible for the study patients had to be resistant to platinum and paclitaxel pretreated. RESULTS: Forty-one patients entered the study. The median interval from the previous chemotherapy was 3.9 months. The median number of previous chemotherapeutic regimens was 2. Severe toxicities included neutropenia (41% of patients), leukopenia (29%) and thrombocytopenia (13%). Thirty-five patients are assessable for response. Nine patients responded (22% of the eligible, 26% of the assessable), four of them demonstrated complete response to chemotherapy (10% and 12%, respectively), while three patients demonstrated stabilization of their progressive disease. After a median follow-up of 18 months, time to progression is 3 months (range 0.9-14.4), duration of response is 9 months (2.5-11) and median survival is 13 months (2.5-37.4+). CONCLUSIONS: The combination of ifosfamide with oral etoposide appears to have significant but manageable toxicity and encouraging efficacy in platinum resistant ovarian cancer.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/10907957-
heal.identifier.secondaryhttp://annonc.oxfordjournals.org/content/11/5/607.full.pdf-
heal.journalNameAnn Oncolen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2000-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ